Łabuzek Krzysztof, Beil Sonia, Beil-Gawełczyk Julia, Gabryel Bożena, Franik Grzegorz, Okopień Bogusław
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Pharmacol Rep. 2014 Oct;66(5):811-20. doi: 10.1016/j.pharep.2014.05.003. Epub 2014 May 23.
Gambling disorder (GD) is becoming increasingly prevalent both among adults and adolescents. Unfortunately, this disorder is largely underestimated, while it can still lead to serious social and personal consequences, including criminal behavior or suicide attempts. In the past, the only means of treating gambling were psychobehavioral therapies. Nowadays, this disorder could also respond to many drugs from different classes such as opioid antagonists, serotonin selective reuptake inhibitors, mood stabilizers, atypical antipsychotics or glutamatergic agents. This review presents current pharmacological strategies and the results of clinical trials evaluating the efficacy of pharmacotherapy for GD. It also discusses the importance of distinguishing different pathological gambler subtypes such as impulsive, obsessive-compulsive and addictive subtypes as this may have serious pharmacological implications.
赌博障碍(GD)在成年人和青少年中日益普遍。不幸的是,这种障碍在很大程度上被低估了,而它仍可能导致严重的社会和个人后果,包括犯罪行为或自杀企图。过去,治疗赌博的唯一方法是心理行为疗法。如今,这种障碍也可能对许多不同类别的药物有反应,如阿片类拮抗剂、5-羟色胺选择性再摄取抑制剂、心境稳定剂、非典型抗精神病药或谷氨酸能药物。这篇综述介绍了当前的药理学策略以及评估药物治疗GD疗效的临床试验结果。它还讨论了区分不同病理赌博者亚型(如冲动型、强迫型和成瘾型亚型)的重要性,因为这可能具有严重的药理学意义。